Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Milan Bruncko(Abbott Fund), Steven W. Elmore(AbbVie (United States)), Shi-Chung Ng(Abbott (United States)), Thorsten Oost(Abbott (United States)), Barbara Belli, Darlene Martineau(Abbott (United States)), William J. McClellan(Abbott (United States)), Xilu Wang(AbbVie (United States)), Tilman Oltersdorf(Harvard University), Michael Wendt(Abbott Fund), Andrew M. Petros(Abbott Fund), Aaron Kunzer(Abbott Fund), Hong Ding(Abbott (United States)), Xiaohong Song(Abbott (United States)), Haichao Zhang(Abbott Fund), Cheol‐Min Park(Abbott (United States)), Alexander R. Shoemaker(Abbott Fund), Mary K. Joseph(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Michael J. Mitten(Abbott Fund), Paul Nimmer(Abbott Fund)
Cited by 295
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k